ATRION CORP Stock: price and management transactions · United States · SEC (Form 4)Follow the ATRION CORP share price and the full insider trade history of the company, a publicly traded company based in United States. Shares are quoted on the US market, under the oversight of SEC (Form 4). Operating in the Healthcare & Pharma sector, ATRION CORP has logged 62 insider filings. The latest transaction was disclosed on 21 August 2024 (Disposition). Among the most active insiders: STRICKLAND JEFFERY. All data is accessible without an account.
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Σ Sigma AI Analysis Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 21 August 2024
All Executives62 Thresholds0 Prospectus0 Other0
Declarations 62 total
● Officer / CFO · Executives · 21 Aug 2024
118 shares @ US$460.00 100.0% of flow common stock SEC:0001963160-24-000004:0
● Director · Executives · 21 Aug 2024
1,368 shares @ US$460.00 66.8% of flow common stock SEC:0001700366-24-000002:0
● Director · Executives · 21 Aug 2024
6,394 shares @ US$460.00 100.0% of flow common stock SEC:0001085535-24-000004:0
● President & CEO · Executives · 21 Aug 2024
55,500 shares @ US$460.00 82.5% of flow common stock SEC:0001400964-24-000005:0
● Director · Executives · 21 Aug 2024
186 shares @ US$460.00 49.7% of flow common stock SEC:0001920839-24-000002:0
● Director · Executives · 21 Aug 2024
2,678 shares @ US$460.00 100.0% of flow common stock SEC:0001403233-24-000002:0
● Director · Executives · 21 Aug 2024
150,616 shares @ US$460.00 93.4% of flow common stock SEC:0001221109-24-000002:0
◇ President & CEO · Executives · 1 Jul 2024
310.89 shares 0common stock SEC:0001400964-24-000004:0
◇ Director · Executives · 1 Jul 2024
310.89 shares 0common stock SEC:0001221109-24-000001:0
◇ President & CEO · Executives · 1 Jul 2024
310.89 shares 0common stock SEC:0001400964-24-000003:0
◇ Officer / CFO · Executives · 8 Mar 2024
163 shares 0common stock SEC:0001963160-24-000002:0
▲ Director · Executives · 1 Dec 2023
300 shares @ US$319.68 10.4% of flow common stock SEC:0001700366-23-000006:0
Canonical exit: 29 Feb 2024 (T+90) ▲ President & CEO · Executives · 16 Nov 2023
300 shares @ US$300.00 0.3% of flow common stock SEC:0001400964-23-000003:0
Canonical exit: 14 Feb 2024 (T+90) ◆ Director · Executives · 20 Sept 2023
186 shares @ US$444.03 100.0% of flow common stock SEC:0001920839-23-000002:0
▲ Director · Executives · 15 Aug 2023
200 shares @ US$523.35 11.4% of flow common stock SEC:0001700366-23-000005:0
Canonical exit: 13 Nov 2023 (T+90) ◆ Director · Executives · 15 Aug 2023
200 shares @ US$523.35 11.4% of flow common stock SEC:0001700366-23-000003:0
● Director,Chairman of the Board · Executives · 1 Jul 2023
310.89 shares @ US$565.70 0.2% of flow common stock SEC:0001221109-23-000002:1
● President & CEO · Executives · 1 Jul 2023
310.89 shares @ US$565.70 0.6% of flow common stock SEC:0001400964-23-000002:1
◇ Director,Chairman of the Board · Executives · 1 Jul 2023
310.89 shares 0common stock SEC:0001221109-23-000002:0
◇ President & CEO · Executives · 1 Jul 2023
310.89 shares 0common stock SEC:0001400964-23-000002:0
◆ Director · Executives · 23 May 2023
224 shares 0Common Stock SEC:0001104659-23-064588:0
◆ Director · Executives · 23 May 2023
112 shares 0Common Stock SEC:0001104659-23-064585:0
◆ Director · Executives · 23 May 2023
224 shares 0Common Stock SEC:0001104659-23-064586:0
◆ Director · Executives · 23 May 2023
224 shares 0Common Stock SEC:0001104659-23-064589:0
◇ Director · Executives · 1 Jul 2021
310.89 shares 0common stock SEC:0001221109-23-000001:0
25 of 62 declarations
Load more (37 remaining) 关于 ATRION CORP Atrion Corp.(股票代码:ATRI)是一家在美国纳斯达克市场上市的公司。它以医疗应用领域专业产品制造商而闻名,其商业模式专注于工程组件和利基设备,而非大众市场医疗保健产品。对于法国、比利时和瑞士的投资者而言,Atrion 是一家专注于高规格工业医疗保健供应商,业务涵盖医院、临床和家庭护理应用。
该公司成立于20世纪中叶,其核心身份围绕技术制造、专有产品设计和长期客户关系。Atrion 总部位于美国德克萨斯州艾伦。其运营模式强调内部制造、质量控制以及在受监管环境中的工程专业知识。这一工业基础具有战略重要性:在可靠性、精确性和合规性至关重要的业务中,制造技术诀窍可以成为关键的竞争护城河。
Atrion 的核心业务包括流体输送产品,旨在精确填充、容纳、释放或去除受控量的流体或气体。这些产品应用于麻醉、肿瘤学、插管、静脉输液、导管和相关医院用途。该公司还生产支持医院和家庭医疗保健环境中感染控制的产品,以及精选的眼科产品。此外,Atrion 历来强调用于海洋和航空安全应用的高度专业化设备,这进一步强化了其作为利基工程企业的形象。
从竞争角度来看,Atrion 并非一家大型综合性医疗设备巨头;它是一家专业公司。其竞争地位建立在专有设计、技术能力以及为要求严苛的客户提供定制解决方案的能力之上。这可以支持定价纪律和客户粘性,但也意味着该公司比多元化的医疗技术同行更容易受到利基终端市场、制造执行和监管质量标准的影响。
在地理上,Atrion 仍然立足于美国,同时通过国际制造和分销网络服务客户。美国证券交易委员会近期披露的信息表明,该公司持续关注现有产品线、运营连续性和制造效率,而非变革性扩张。因此,该公司的业务概况符合防御性、专业化医疗保健-工业投资案例:适度规模、技术差异化以及服务于基本但狭窄定义市场的多元化产品组合。